Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $104.67, but opened at $114.50. Palvella Therapeutics shares last traded at $113.2750, with a volume of 4,910 shares traded.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. BTIG Research raised their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Mizuho raised their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. HC Wainwright lifted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Price Performance

The firm’s 50 day moving average is $120.96 and its 200 day moving average is $107.68. The firm has a market cap of $1.63 billion, a P/E ratio of -27.23 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts expect that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new stake in Palvella Therapeutics during the first quarter worth about $28,000. Group One Trading LLC boosted its stake in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics during the third quarter worth about $36,000. China Universal Asset Management Co. Ltd. bought a new stake in Palvella Therapeutics during the fourth quarter worth about $167,000. Finally, Keybank National Association OH purchased a new position in Palvella Therapeutics in the first quarter worth about $228,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.